Genetic Modification of Cytokine Signaling to Enhance Efficacy of CAR T Cell Therapy in Solid Tumors

Navid Ghahri-Saremi1, Behnia Akbari1, Tahereh Soltantoyeh1, Jamshid Hadjati1, Saba Ghassemi2* and Hamid Reza Mirzaei1*

1 Department of Medical Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran, 2 Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States

Chimeric antigen receptor (CAR) T cell therapy has shown unprecedented success in treating advanced hematological malignancies. Its effectiveness in solid tumors has been limited due to heterogeneous antigen expression, a suppressive tumor microenvironment, suboptimal trafficking to the tumor site and poor CAR T cell persistence. Several approaches have been developed to overcome these obstacles through various strategies including the genetic engineering of CAR T cells to blunt the signaling of immune inhibitory receptors as well as to modulate signaling of cytokine/chemokine molecules and their receptors. In this review we offer our perspective on how genetically modifying cytokine/chemokine molecules and their receptors can improve CAR T cell qualities such as functionality, persistence (e.g., resistance to pro-apoptotic signals) and infiltration into tumor sites. Understanding how such modifications can overcome barriers to CAR T cell effectiveness will undoubtedly enhance the potential of CAR T cells against solid tumors.

Keywords: cytokines, chemokines, genetic modification, CAR T cell, immunotherapy, solid tumors

INTRODUCTION

Surgery, chemotherapy and radiation therapy have been the principal cornerstones of cancer treatment since the middle of the last century. The development of novel molecular targeted therapies and immunotherapies such as immune checkpoint inhibitors and CAR T cells, among others, have led to a paradigm shift in the treatment of cancer patients (1, 2). Exciting progress with CD19-CAR T cells for the treatment of certain pediatric and young adult patients with B cell acute lymphoblastic leukemia has led to the successful approval by the US Food and Drug Administration (FDA) in August 2017 (3, 4). Despite the advancement in the treatment of blood cancers with CAR T cells, treating solid tumors has been challenging in part due to heterogeneous tumor antigen expression, the presence of immunosuppressive and hostile tumor microenvironment (TME) that exacerbates CAR T cell exhaustion and apoptosis, and insufficient infiltration into the tumor sites (5–7).

It is well-recognized that cytokines, chemokines and their receptors play pivotal roles in regulating the functional and phenotypic features of CAR T cells; influencing parameters such as persistence, trafficking, memory cell formation and proliferation. All of which are essential determinants of an effective therapy (8, 9). Cytokines and chemoattractant cytokines (also known
as chemokines) are small glycoproteins that regulate immune cell activation, differentiation, growth and trafficking. Moreover, these small glycoproteins not only have critical roles in shaping of immune responses against different types of pathogens and tumor antigens but also determine which type of immune responses (e.g. cell-mediated vs. humoral immunity) should be developed to effectively eliminate their targets. Each cytokine has different functions and can provoke different responses depending on the target, cellular source and different phase of immune response. These small glycoproteins can have proinflammatory and anti-inflammatory properties which partly depend on the nature of target antigen and the context that an immune response initiated (10). Although systemic or local administration of cytokines in combination with CAR T cells improved antitumoral efficacy of these cells, some adverse effects including toxicity or even death, have been considered as significant barriers for systemic application of cytokines (11, 12).

Considering the importance of cytokines, chemokines and their receptors in the biology and immunology of CAR T cells, several investigators have tried to modulate the profile of cytokines and chemokines in CAR T cells or equip them with cytokines, chemokines or their receptors aiming to alleviate CAR T cell overactivation (i.e. cytokine release syndrome(CRS)) and/or overcome barriers (e.g. harsh immunosuppressive tumor microenvironment, suboptimal trafficking of CAR T cells to tumor site and activation-induced cell death) to their effectiveness. There are various strategies to genetically manipulate CAR T cells to enhance the overall functionality of these engineered cells against various types of tumors. For example, one of these strategies is the use of CRISPR-based gene editing technology to blunt the expression of cytokine genes responsible for CAR T cell dysfunction or CAR T cell-related toxicity (e.g. CRS). In this system, a single guide RNA (sgRNA) directs CAS9 endonuclease to the target gene. Binding of sgRNA to targeted gene activates CAS9 endonuclease which then leads to cleavage and knocking out of the target gene (13, 14). Another example is incorporation of truncated cytokine receptors into CAR T cells (through viral transduction) which lack a specific intracellular domain. These receptors block signal transduction of inhibitory cytokines and therefore enhance the persistence and effector function of CAR T cells (15, 16). Another approach is the co-expression of CAR construct with desirable cytokine through the 2A linker system or two vector systems. 2As are viral oligopeptides that can mediate cleavage of translated construct which leads to co-expression of both cytokine and CAR on T cells at the same time and expression level (17, 18). SynNotch receptor system and inducible promoter systems are examples of inducible expression of cytokines (19, 20). In the SynNotch receptor system, the recognition of specific antigen, mediates transcriptional activation of a specific cytokine gene in CAR T cells (21). Also, there are other strategies such as inverted cytokine receptors (ICRs) in which ectodomain of inhibitory cytokine is fused with endodomain of immunostimulatory cytokines (22), and membrane tethered cytokines that can be transferred via viral transduction or sleeping beauty (SB) system (excision and insertion of SB transposon into TA dinucleotide repeat of target-cell genome) (Table 1)(34, 46). In this review we discuss how employing various genetic strategies like incorporating dominant negative receptors, inverted cytokine receptors and immunostimulatory cytokines not only can diminish and/or reverse negative CAR T cell regulators in the tumor microenvironment but also can augment positive regulators of CAR T cells (e.g. proliferation and persistence) in solid tumors.

**IMPROVING CAR T CELL PERSISTENCE**

It is well-known that persistence of CART cells is directly correlated with durable clinical remissions in patients with cancers (47, 48). In fact, poor persistence potentially hinders the long-term therapeutic effects of CAR T cell in vivo. It has been shown that several parameters can affect the survival of adoptively transferred CAR T cells (49). In the two following sections, we discuss how genetic modification of CAR T cells to overexpress cytokines or their receptors makes prolong their survival.

**Production of Less Differentiated CAR T Cells**

It is well-documented that the differentiation status of CAR T cells plays a prominent role in therapeutic success. It seems this successful therapeutic outcome is largely depend on the fact that less differentiated CAR T cells (e.g. naïve T cells (TN), stem cell memory (TSCM) and central memory (TCM)) are correlated with improved expansion, prolonged in vivo persistence, and long-term anti-tumor control (50).

As a result, many studies have focused on the production of CAR T cells with a less differentiated phenotype through employing different pharmacological and genetic mechanisms. For instance, less differentiated CAR T cells have been generated through inclusion of cytokine genes (e.g. IL-9, IL-7, IL-15 and IL-21) in the CAR gene construct (51, 52) and incorporation of cytokine-induced JAK/STAT signaling domains in the CAR gene construct (53–55). Using a hepatocellular carcinoma model, it has been revealed that co-incorporation of IL-15 and IL-21 genes into the anti-GPC3 CAR construct, leads to greater proliferation capacity, enhanced persistence and survival and elevated proportion of stem cell memory CAR T cell subpopulation (23). Adachi and colleagues also showed that IL-7 and CCL19 co-expressing CAR-T cells become differentiated into central memory CAR T cells with superior tumor-infiltrating capacity and higher persistence rate in a P815-hCD20 (mastocytoma) mouse model (24). Incorporation of IL-15 into CAR construct could also enhance stem-cell like memory CAR T cell portion with superior tumor killing ability and reduced expression of PD-1 receptor in neuroblastoma-bearing mice compared to conventional CAR T cells (25).

Using JAK/STAT signaling domains downstream of cytokine receptors is also another tactic for blunting CAR T cells differentiation towards terminally differentiated phenotype. The γc-family cytokine-stimulated JAK/STAT signaling pathway is shown to dampen CAR T cells phenotype into terminally-
differentiated CAR T cells. Using a CAR construct encoding a truncated cytoplasmic domain from IL-2Rβ and a STAT3-binding tyrosine-X-X-glutamine (YXXQ) motif, together with the CD3ζ and CD28 domains [also referred to as 28-DIL2RB-ζ (YXXQ)], it has been exhibited that the 28-DIL2RB-ζ(YXXQ) CAR T cells are highly proliferative and are not vulnerable to the acquisition of terminally differentiated phenotype in a B-ALL experimental model. Compared to CAR T cells without STAT3 motif, 28-DIL2RB-ζ(YXXQ) CAR T cells maintained proliferation, IL-2 secretion, cytokine polyfunctionality. These results suggest a key role of STAT3 in suppressing terminal differentiation of T cells, which is consistent with recent human and mouse studies (54, 55). Modified CAR T cells also expressed markers related to stem cell like memory phenotype (such as, CD27, CD28 and CD95) (53). These characteristics have been also described in less differentiated memory T cells (56, 57).

Currently, a phase 1 clinical trial is being planned to investigate the effect of IL-15 and IL-21 armored Glypican-3-specific CAR T cells for pediatric solid tumors (NCT04715191).

Production of CAR T Cells Resistant to Pro-Apoptotic Signaling Cues

Overexpression of proapoptotic proteins such as Bid, Bim and FasL has been related to progerious T-cell differentiation and loss of self-renewal capacity (58). Resistance to pro-apoptotic signals and/or augmentation of anti-apoptotic signaling pathway are supposed to be an alternative option for promoting CAR T cell survival and persistence (49). TGF-β as a potent immunosuppressant of TME is produced by different cell types such as cancer associated fibroblasts, mesenchymal stem cells, lymphatic epithelial cells and blood endothelial cells (59). It is generally accepted that TGF-β inhibit T cell activation and proliferation likely due to induction of T cell apoptosis via either proapoptotic-dependent (e.g. BIM) or independent pathways (60–62). To blunt its suppressive effects on CAR T cells and to enhance the overall antitumor function of CAR T cells, CRISPR-mediated TGFβRII-knockout CART cells (TGFβRII.KO CART cells) have been developed. TGFβRII.KO CART cells displayed higher survival and proliferation rates and were more resistant to exhaustion in the pancreatic carcinoma-bearing mice (27). IL-15 is known as a general inhibitor of apoptosis, which possesses potential therapeutic properties. Overexpression of murine IL-15 in CAR T cells has led to generation of CAR T cells with enhanced persistence, lower level of PD-1 expression, being more resistant to proapoptotic signals (probably due to augmentation of BCL-2 level) and improved antitumor immune response in a B16 melanoma model in vivo compared to conventional 2nd generation CAR T cells (26). In addition, IL-7 signaling through STAT5 has shown to be in favor of CAR T cell resistance to proapoptotic signals. In a study, Shum and colleagues have shown that constitutive signaling downstream of IL-7 receptor, through

| TABLE 1 | Novel genetic modifications in cytokine, chemokine and their receptors to enhance the efficacy of CAR T cell therapy. |

| Strategies | Cytokines & Chemo- | Genetic modification | Reference |
| --- | --- | --- | --- |
| Improving persistence | IL-15 & IL-21 | Overexpression | 23 |
| | IL-7 & CCL9 | Overexpression | 24 |
| | IL-15 | Overexpression | 25, 26 |
| | TGFβ | CRISPR-mediated knockout | 27 |
| | IL-7 | CRISPR-mediated knockout | 28 |
| Converting immuno-suppressive to immuno-promoting signals | IL-4/R/IL-7R | CRISPR-mediated knockout | 29 |
| | IL-4/R/IL-21R | CRISPR-mediated knockout | 22 |
| | TGFβ/IL-7R | CRISPR-mediated knockout | 30 |
| | GM-CSF/IL-18R | CRISPR-mediated knockout | 31 |
| Overcoming Exhaustion | TGFβRII | Truncated | 15 |
| | aPD1/TGFβ trap | Overexpression | 32 |
| | IL-18 | Inducible expression | 20 |
| | IL-7 | Overexpression | 33 |
| | IL-15 | Membrane tethered | 34 |
| AICD prevention | IL-7 | CRISPR-mediated knockout | 28 |
| Improving infiltration | CCR6 | Overexpression | 35 |
| | CCR2b | Overexpression | 18, 36 |
| | CCR4 | Overexpression | 37 |
| | CXCR2 | Overexpression | 38 |
| CRS and neurotoxicity inhibition | IL-6 | shRNA-mediated Knockdown | 39 |
| | mbaIL-6 | Truncated | 40 |
| | GM-CSF | CRISPR-mediated knockout | 41 |
| | GM-CSF & aIL-6/IL-1RA | CRISPR-mediated knockout & secreting neutralizing antibody & antagonist | 14 |
| Endogenous immune system activation | IL-7 & CCL19 | Overexpression | 24 |
| | IL-18 | Overexpression | 42 |
| | IL-12 | Overexpression | 43, 44 |
| | IL-36βy | Overexpression | 45 |

ICR: inverted cytokine receptor; CRS: cytokine release syndrome; mbaIL6: membrane-bound IL-6 receptor; aIL-6R: anti-IL-6 receptor antibody; IL-1RA: IL-1 receptor antagonist.
using CD34 ectodomain and endodomain of IL-7Rα (C7R), leads to upregulation of anti-apoptotic protein BCL2 and downregulation of proapoptotic protein CASP8 (Caspase-8) in an orthotopic glioblastoma mouse model (28). Altogether, these findings indicate that genetic modification of cytokines and their receptors might make CAR T cells more resistant to negative regulators of persistence through reprogramming of CAR T cell differentiation and abrogation of proapoptotic signaling.

**CONVERTING IMMUNOSUPPRESSIVE SIGNALS TO IMMUNOPROMOTING SIGNALS**

Immunosuppressive cytokines including IL-10, TGFβ and IL-4, are one of the key components of TME contributing to CAR T cell dysfunction. These cytokines induce immunosuppression via several mechanisms such as recruitment and activation of regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSCs), inhibition of the effector function of CAR T cells. In addition, they can inhibit the activity of several endogenous antitumor immune cells like T cells, NK cells, dendritic cells, and M1 macrophages. Immunosuppressive cytokines such as TGFβ can also disrupt the balance between TH1 and TH2 cells toward TH2 cells which leads to induction of other suppressive cytokines (e.g. IL-4) (63). To overcome cytokine-induced immunosuppression in the CAR T cells, Mohammed and colleagues have developed an inverted cytokine receptor IL-4R/IL-7R [i.e. 4/7 ICR, consisted of an IL-4R exodomain fused to an IL-7R endodomain]. Upon ligation to immunosuppressive cytokine IL-4, this chimeric switch receptor not only could significantly restrict the immunosuppressive effects of IL-4 but also could successfully convert inhibitory signals to IL-7 immunostimulatory signals. This immunostimulatory downstream signaling could prevent and/or restore CAR T cell exhaustion and dysfunction as well as could improve CAR T cell survival in a harsh TME of pancreatic cancer experimental model (29). In another study, Wang et al., have showed that overexpression of IL-4R/IL-21R inverted cytokine receptor (4/21 ICR) in CAR T cells could promote TH17-like polarization and enhance tumor specific cytotoxicity of 4/21 ICR-engineered CAR T cells in an IL-4-enriched hepatoma tumor milieu via activation of STAT3 pathway. Also, these cells were characterized by enhanced persistence and could successfully control established IL-4-secreting tumors in vivo (22). Weimin et al., have also reported that equipment of CAR T cells with chimeric cytokine switch receptor TGFβ/IL-7 not only could enhance their cytotoxic activity, cytokine production ability (e.g. IFNγ and TNFα) and proliferation capacity but also could reduce the expression of inhibitory receptors (e.g. PD-1 and LAG-3) in a prostate cancer model (30). Chimeric cytokine switch receptor GM-CSF/IL-18R (GM18) overexpressed in CAR T cells could also confer a higher rate of cellular expansion, cytokine production and sustain cytotoxic activity in a chronic antigen-stimulated condition of various preclinical EPHA2 or HER2 positive solid tumor models, compared to unmodified CAR T cells (31). In aggregate, it seems converting immunosuppressive cytokine signals to immunopromoting signals may be a promising strategy for improving CAR T cell functionality and longevity.

**OVERCOMING CAR T CELL EXHAUSTION**

CAR T cell exhaustion represents a substantial barrier to the eradication of tumors and is associated with poor clinical outcome. Exhaustion is a common feature of tumor-infiltrating CAR T cells. Immunological exhaustion is characterized by progressive loss of T cell effector functions and proliferative capacity, sustained expression of inhibitory receptors (e.g. PD-1), increased susceptibility to apoptosis and activation of a transcriptional state distinct from that of functional effector or memory T cells (64). Tumor cells, and their surrounding immunosuppressive cells and cytokines are supposed to contribute to this exhausted T cell phenotype (65). As exhausted CAR T cells showed impaired effector function and failed to eradicate tumors (66), thus reversing this state can potentiate/restore the function of exhausted CAR T cells and thereby restore a robust antitumor response.

It has been shown that genetic modification of CAR T cells in this particular case-cytokine overexpression (e.g. IL-18, IL-15 and IL-7) or repression/abrogation (e.g. TGFβR) can be a powerful approach for reverting CAR T cell exhaustion. TGFβ is a well-known immunosuppressive cytokine. This cytokine can induce T cell exhaustion through downstream signaling molecules (e.g. SMAD2 and SMAD3) of its receptor (e.g. TGFβRII). Therefore, genetic modification of TGFβR signal transduction can be an efficient method for the prevention of CAR T cell exhaustion. One of the examples is generation of dominant negative TGFβRII CAR T cells which have truncated TGFβRII that lack an intracellular signaling domain. This method makes CAR T cells resistant to exhaustion, enhances their proliferation and cytokine production abilities and confers long-term persistence with effective antitumor response against PSMA positive prostate cancer cells (15). In another study using CRL5826 positive melanoma cells, Tang and colleagues have demonstrated that knocking out the endogenous TGFβRII in CAR T cells with CRISPR/Cas9 technology could reduce the induced Treg conversion and prevent the exhaustion of CAR T cells (27). Secretion of bispecific protein of anti-PD-1 fused with TGF-β trap has also shown to enhances antitumor efficacy of CAR T cells through attenuating inhibitory T cell signaling, enhancing T cell persistence and expansion, and improving effector function and resistance to exhaustion in a prostate cancer xenograft mouse model (32). It has been well-documented that overexpression of cytokines (e.g. IL-18, IL-7 and IL-15) can prevent/revert CAR T cell exhaustion. Chmielewski and colleagues have revealed that CAR T cells engineered with inducible IL-18 release, as a potent immune modifier, can prevent CAR T cell exhaustion in large pancreatic and lung tumor models (20). Previous studies have also suggested an anti-exhaustive role for IL-7 (67). IL-7 secreting CAR T cells were also shown to express lower levels of exhaustion markers (e.g. PD-1 and LAG3) and higher levels of anti- transcription factor TCF-1, a transcription factor that is supposed to counteract exhaustion programs, in a gastric cancer experimental model (33, 68, 69). IL-15 has also proven beneficial in antagonizing CAR T cell exhaustion (70, 71). In agreement with these reports, Singh and colleagues have demonstrated that CAR T cells expressing a membrane-bound chimeric IL-15 (mbIL15) are not only characterized by long-term persistence with a memory stem-cell phenotype but also express lower levels of exhaustion...
markers and higher expression level of anti-exhaustive transcription factor TCF-1 in a xenograft mouse model of leukemia (34). Furthermore, Narayan et al. have conducted a phase 1 clinical trial for dominant negative TGFβR CAR T cell (PSMA-directed/ TGFβ-insensitive CAR T cells) against metastatic castration-resistant prostate cancer (CRPC). Cohorts 1 and 2 have been done without observed dose-limiting toxicity (DLT). Intriguingly, a cytokine release syndrome has been observed that is reversible and responsive to tocilizumab (72).

OVERCOMING ACTIVATION-INDUCED CELL DEATH (AICD)

Activation-induced cell death (AICD) is a major mechanism of T cell homeostasis and acts to prevent excessive T cell responses towards possible subsequential autoimmunity (73). Induced by repeated antigen stimulation under particular conditions, T cells undergo apoptosis in a controlled manner through the engagement of death receptors (e.g. Fas) and activation of specific caspases (e.g. caspase-8). Although AICD is generally considered as a T cell regulatory mechanism in the physiological conditions, this process is also triggered in the TME following chronic activation of tumor-infiltrating T cells (e.g. adoptively transferred CAR T cells), leading to apoptosis of tumor-redirected CAR T lymphocytes, thereby, hampering their full therapeutic potential (74).

Several efforts have been made over the years to overcome this barrier aiming to preserve CAR T cell efficacy and improve their survival and persistence in the TME. It has been shown that various cytokines are involved in either induction (e.g. TNFα and IL-2) or prevention (e.g. IL-7 and IL-15) of AICD. As mentioned above, Shum et al., have exhibited that CAR T cells supporting constitutive signaling downstream of IL-7 receptor have lower levels of Fas and proapoptotic protein CASP8 (Caspase-8), two major proteins that are involved in AICD (28). These findings highlight the role of IL-7 and its related signaling pathways in the inhibition of AICD. IL-15 is another potential cytokine for antagonizing AICD. The role of IL-15 in preventing AICD has been very well established (75). For instance, it has been shown that engineering of CAR T cells with membraned-bound IL-15 makes them more resistant to AICD (34).

In other hand, it has been reported that cytokines like IL-2, IL-4, TNFα and IFNγ are in favor of AICD induction (76). Therefore, it seems that genetic abrogation of these cytokines may alleviate the role of these cytokines in the induction of AICD in CAR T cells, however, it is remained to be further studied in future (76). In conclusion, these findings indicate that genetic modification and/or targeting of specific cytokine genes and/or their receptors may be a good option for overcoming activation-induced cell death in the CAR T cells, thereby, improving the efficacy of CAR T cell therapy.

IMPROVING CAR T CELL INFILTRATION INTO TUMOR SITE

Suboptimal trafficking of CAR T cells to the tumor sites represents another hurdle to CAR T cell therapy. Several reports have demonstrated that enhanced trafficking of adoptively transferred-CAR T cells to tumor sites is correlated to their therapeutic efficacy and clinical outcome in the cancer patients (77–79).

Various barriers that hinder optimal trafficking of CAR T cells to the tumor sites have been described. These barriers include: i) chemokine/receptor mismatch between the CAR T cell chemokine receptors and the chemokines secreted by tumors (e.g. such as CXC1L1, CXC1L3 and CXC1L2), ii) low levels of tumor-derived chemokines for which effector CAR T cells lack receptors, iii) abnormal tumor vascularity and iv) physical (e.g. extracellular matrix (ECM)) and cellular barriers (e.g. cancer-associated-fibroblasts [CAFs]) (80, 81). Although various strategies such as local delivery of CAR T cells, targeting tumor-related cellular and physical barriers (e.g. generation of anti-FAP CAR T cells targeting CAFs and CAR T cells to overexpress heparanase, an ECM-degrading enzyme) and targeting abnormal tumor vascularity (e.g. generation of CAR T cells targeting VEGFR2 expressed tumor-associated blood vessels) have been employed to overcome CAR T cell infiltration, genetic modification of chemokine receptors, among the others, has been the most common strategy to improve CAR T cell infiltration into the tumor bed (82–84). Genetic modifications of these molecules have widely been used as a novel strategy for conferring new migratory capacity to administrated CAR T cells. Jin et al. showed that anti-EGFR CAR T cell migration to lung cancer site was enhanced by overexpression of CCR6, which recognizes lung cancer-produced CCL20, a chemokine that is highly expressed by lung adenocarcinoma cells. The authors also found that overexpression of CCR6 has no negative effects on the CAR T cell effector functions and their phenotype. In addition, mice receiving CCR6-overexpressing CAR T cells showed enhanced survival and an improved antitumor activity compared to mice receiving conventional unmodified CAR T cells (35). As chemokine CCL20 is also overexpressed in various types of cancer like colon adenocarcinoma (COAD), rectum adenocarcinoma (READ) and stomach adenocarcinoma (STAD), therefore, overexpression of CCR6 in CAR T cells might be an effective strategy to overcome insufficient infiltration of CAR T cells into CCL20-expressing tumor sites. CCR2b is a chemokine receptor that poorly expressed in all resting and activated peripheral blood T cells and IL-2 activated malignant pleural mesothelioma (MMP)-infiltrating lymphocytes. To promote infiltration of CAR T cells into MMP-bearing sites, Moon et al., generated an antimesoCAR T cells overexpressing CCR2b (i.e. CCR2b-mesoCAR T cells). Their data showed that overexpression of CCR2b in mesoCAR T cells can significantly increase their migration to mesothelin+ MMP sites in vivo, leading to enhanced antitumor effects (18). A separate report showed that expression of CCR2b on GD2-CAR T cells significantly increase migration of CAR T cells toward CCL2 secreting neuroblastoma cells (36). DiStasi et al., have reported that overexpression of CCR4 on anti-CD30 CAR T cells improved the trafficking of these engineered T cells toward CCL17/Hodgkin lymphoma cells (37). Another report also proved that overexpression of CXCR2 on CAR T cells increase homing capability of CXCR2-expressing CAR T cells toward hepatocellular carcinoma cells-producing CXCL1, CXCL2,
CXCL3, CXCL5, CXCL6, and CXCL8 (38). In aggregate, these data indicate that genetic modification of chemokine receptors in CAR T cells may be a novel strategy to improve the efficacy and homing capabilities of adoptively transferred CAR T cells.

MODULATING CYTOKINE RELEASE SYNDROME AND NEUROTOXICITY FOLLOWING CAR T CELL THERAPY

Systemic cytokine release [also known as cytokine release syndrome (CRS)] is a common but potentially fetal adverse event following CAR T cell therapy (85). Following the administration of CAR T cells, an exaggerated systemic immune response mediated by activated CAR T cells and various endogenous immune system components (e.g., monocytes/macrophages) is initiated. This acute systemic inflammatory response is mainly triggered by the release of a large amount of inflammatory mediators such as cytokines (e.g., IL-6, IL-1, IFN-g and GM-CSF) and chemokines (e.g., MCP-1 and MIP-1α) (86). This acute inflammatory response also induce endothelial and organ injury, which leads to microvascular leakage, heart failure and even death (85). Therefore, timely and properly interventional strategies that control CRS symptoms better or even to prevent CRS and neurotoxicity associated with CAR T cell therapy while preserving the efficacy of CAR T cell treatment is of great importance and are urgently needed. Unlike hematological malignancies, the data on CRS incidence in solid tumors is limited (38).

Since it has been shown that IL-6 is the key molecule of CRS, many studies have recently focused to reduce and/or overcome IL-6-mediated CRS (91, 92). To do so, two independent studies have knocked down IL-6 gene in anti-CD19 CAR T cells via incorporation of short hairpin RNA (shRNA) into CAR construct (termed ssCART-19) (39, 92). Their data revealed that IL-6 released from CAR T cells not only cause CRS but also induces sequestration of proinflammatory cytokines in the monocytes which altogether participate in the incidence and exacerbation of CRS. The authors also found that ssCART-19 cells produce lower levels of IL-6 and significantly reduce IL-6 secretion by monocytes in xenograft mouse model of leukemia. No significant difference in CAR T cell functionality in terms of proliferation and cytotoxicity was observed in both ssCART-19 cells and regular CART-19 cells. Reduced production of IL-6 by both CAR T cells and monocytes might lead to a significant reduction in the CRS incidence in the patients receiving CAR T cell therapy (39, 92).

In another study, Tan et al., have engineered anti-CD19 CAR T cells to express a nonsignaling membrane bound IL-6 receptor (mbaIL6). In vitro testing of mbaL6-expressing CAR T cells (termed mbaIL6CAR T cells) revealed similar cytotoxic and proliferative abilities compared to conventional CAR T cells. Moreover, mbaIL6CAR T cells were able to neutralize macrophage-derived IL-6 while preserving their powerful antitumor activity in vitro. In vivo studies using CD19+ ALL cell line Nalm-6 also showed that anti-CD19 CAR T cells were effective in targeting of CD19+ tumor cells regardless of mbaIL6 expression. However, level of human IL-6 in mice was significantly diminished in the mbaIL6CAR T-treated tumor-bearing mice compared to unmodified anti-19CAR T cells (40).

GM-CSF has been also identified as a crucial cytokine in the development of neurotoxicity and CRS. Elevated levels of GM-CSF promote secretion of IL-6, IL-8 and MCP-1, as other important CRS biomarkers, from monocytes (41). To prevent or reduce the risk of CRS and neuroinflammation mediated by GM-CSF following CAR T cell therapy, Sterner and colleagues have utilized lenzilumab, a GM-CSF neutralizing antibody, in combination with anti-CD19 CAR T cells. Their data showed that blocking GM-CSF leads to enhanced CART cells proliferation and efficacy. They found that blocking of GM-CSF has no significant effect on the tumor killing capacity of CAR T cells in the presence of monocytes in vitro. In line with their in vitro findings, in vivo studies also revealed that lenzilumab not only inhibits GM-CSF effector functions, but also preserves anti-leukemia activity. In vivo studies also proved that CAR T 19 cells in combination with GM-CSF neutralizing antibody could significantly reduce neuroinflammation and prevent of CRS. To rule out any critical role for GM-CSF in CAR T cell function, the authors also generated GM-CSF knockout anti-CD19 CAR T cells (termed GM-CSFK.O CAR T 19 cells) using CRISPR/Cas9 gene editing technology. Their findings revealed that GM-CSFK.O CART19 cells could significantly reduce GM-CSF production compared to conventional CART19 cells. In addition, gene-editing strategy had no interventional effect on the production of other effector cytokines (e.g., IFNγ and IL-2) in the gene-edited anti-CD19 CAR T cells in vitro. While GM-CSFK.O CAR T19 cells were not able to produce GM-CSF, they could control leukemia growth in vivo (41). Another example is production of CRISPR-edited GM-CSF knockout CAR T cells secreting anti-IL-6 scFv and IL1RA with TCR knockout (CARTaIL6/IL1RA with GM-CSF/TCR KO). Compared to GM-CSF wild type counterparts, CARTaIL6/IL1RA with GM-CSF/TCR KO showed similar cytotoxicity and reduced GM-CSF production against CD19+ Nalm6 leukemia cells. Also, a pilot study of three patients, one with refractory Non-Hodgkin lymphoma (NHL) and two with multiple myelomas (MMs) with CARTaIL6/IL1RA with GM-CSF/TCR KO showed 3/3 complete response, 2/3 with no CRS incidence, one with grade 2 CRS incidence and no neurotoxicity which proved safety and efficacy of CARTaIL6/IL1RA with GM-CSF/TCR KO. In addition, cytokine analysis revealed a low level of GM-CSF, IL-6 and IL-1β and elevated level of IL1RA in the treated patients (14). It was also reported that genetic disruption of GM-CSF in the CAR T cells can abolish macrophage-dependent secretion of CRS mediators, including IL-6, IL-8 and MCP-1 (93). Furthermore, Kang et al. have conducted a clinical trial to evaluate safety and efficacy of ssCART-19 in patients with acute lymphoblastic leukemia (CLL). Their data exhibited a
significant reduction of severe CRS incidence in patients receiving ssCART-19 compared to those who received regular CART-19 (39). Neurotoxicity, also referred to as immune effector cell-associated neurotoxicity syndrome (ICANS), is another CAR T cell–related toxicity which often occurs and correlates with CRS, but it has also been sometimes reported to occur independently from CRS. The data obtained from preclinical studies revealed that monocyte-derived IL-1 appeared to mediate neurotoxicity and CRS (94). Stimulation of monocytes by GM-CSF following CART cell therapy was shown to be related to neuroinflammation in tumor-bearing mice (41). High levels of IL-6 and GM-CSF was detected in the cerebrospinal fluid (CSF) of non-human primate models of neurotoxicity following CART cell therapy (95). After CAR T cell therapy, cytokines, especially IL-1 and IL-6 and GM-CSF, have been demonstrated to promote systemic inflammation which associates with the development of severe neurotoxicity (96). GM-CSF has been also described as the cytokine most significantly correlated to the development of neurotoxicity following CART cell therapy in the ZUMA-1 clinical trial (97). These findings not only describe the crucial role of cytokines in pathogenesis of neurotoxicity but also highlight how genetic modification of cytokines by various strategies like shRNA-mediated knocking down of cytokine genes, design of nonsignaling membrane bound cytokine receptors and knocking out of cytokine genes in CAR T cells may significantly prevent and/or alleviate the post-CAR T cell therapy-related neurotoxicity.

In the case of solid tumors, although rare, but CRS incidence can occur much like happen in B-NHL as characterized by local CRS (L-CRS or compartmental-CRS) followed by systemic CRS (S-CRS). It seems immunosuppressive TME and suboptimal trafficking of CAR T cells to tumor bed prevent optimal tumor antigen recognition and therefore limit full activation of CAR T cells and subsequent cytokine release and CRS incidence (87). There are a few reports on the incidence of compartmental CRS in a patient with recurrent ovarian cancer after treatment with anti-mesothelin CAR T cell (98) or the occurrence of severe CRS in a 45-year-old patient with malignant mesothelioma after the treatment with anti-EpCAM CAR T cells (87). Altogether, these data suggest that genetic modification of cytokines and receptors in CAR T cells would be an appealing strategy to prevent CRS and neurotoxicity or reduce its severity without affecting the antitumor potential of CAR T cell therapy.

**ACTIVATION OF ENDOGENOUS IMMUNE SYSTEM**

Although genetically-modified CAR T cells have shown promising results compared to conventional CAR T cells, yet converting the CAR T cell response to a stronger and more continual one remains to be an important issue. CAR T cells are programmed to recognize one to three specific antigens utmost, but due to the pressure of immune selection and tumor antigen heterogeneity, some antigen-negative tumor variants can outgrow and outperform the a successful antitumor function of administrated CAR T cells. One overcoming solution would be the induction of epitope spreading towards antigens beyond those recognized by adoptively transferred CAR T cells. Epitope spreading is characterized by the enhancement and diversification of the endogenous T-cell–mediated immune response against non-CAR antigenic epitopes (99, 100). Based on this strategy, stimulation of endogenous immune cells along with CAR T cells can collaboratively target tumor cells (Figure 1). It seems that the inflammatory environment made by engineered CAR T cells can result in priming of endogenous immune cells against additional target antigens that is beyond the CAR target and are present on tumor cells.

Various studies have shown that infiltration of endogenous immune cells (in particular T lymphocytes) into the tumor sites can expand the efficacy of CAR T cell therapy (87, 101). In line with this notion, Adachi et al., reported that overexpression of IL-7 and CCL19, as two essential cytokines for generation of less-differentiated, long-lived non-exhausted (CAR) T cells and recruitment of endogenous DCs and T cells, in CAR T cells (termed 7x19 CAR T cells) increased infiltration of DCs and T cells into tumor sites following 7 × 19 CAR T cell therapy. They also found that depletion of recipient T cells before 7 × 19 CAR T cell therapy diminished the therapeutic efficacy of these genetically-modified CAR T cells, indicating that CAR T cells and endogenous immune cells collaboratively exert antitumor activity (24). Avanzi and colleagues also demonstrated that IL-18 armored CAR T cells, unlike unmodified CAR T cells, were able to activate and recruit endogenous antitumor immune effector cells such as CD8 T cells, DCs, NK cells and NKT cells into B-ALL tumor sites and metastatic ovarian tumor sites broadening the antitumor response beyond the CAR target (42). Arming CAR T cells with IL-12, a potent immunostimulatory cytokine that activates the innate and adaptive cellular immune system, was also shown to enhance antitumor efficacy through TME reprogramming and activation of endogenous immune system with antitumor function in both lymphoma and ovarian tumor models (43, 44). However, it should be noted that in study conducted by the Koneru et al., the total concentration of serum IL-12 was consisted of both endogenous and exogenous IL-12, and was not a reflection of IL-12 solely produced by IL-12 armored-CAR T cells (102). In another independent study, Kueberuwa et al. have exhibited that IL-12-expressing anti-CD19CAR T cells not only directly kill lymphoma cells, but also recruit host antitumor immune effector cells to an anti-cancer immune response in the lymphoreplete mice (103). CAR T cells secreting IL-36γ have also shown higher expansion rate with superior antitumor function compared with unmodified CAR T cells. Their data also revealed that IL-36γ armed CAR T cells activate endogenous antigen-presenting cells (APCs) and T cells through promotion of a secondary antitumor response and delayed the progression of antigen-negative tumor challenge in an experimental model of B-cell lymphoma (45). A separate study has also reported that effective CAR T cell antitumor activity of IL13Ra2-CAR T cells against mouse syngeneic glioblastoma (GBM) is significantly dependent on the activation of patient-derived endogenous T cells and monocyte/
macrophages at the tumor site in an IFNγ-dependent manner (101). Currently, a phase 2 clinical trial for IL-7 and CCL-19 expressing CAR T cells against Refractory/Relapsed B Cell Lymphoma is in recruiting status (NCT03929107). Altogether, these findings highlight the importance of activation of endogenous immune system in the context of CAR T cell therapy. It seems CAR T cells act as immunomodulatory adjuvant for the activation of host immune cells. This insight strongly supports the need to consider targeting/engaging host immunity to improve the efficacy of CAR T cell therapy. Moreover, activation of endogenous immune system can additionally prevent or delay the progression of antigen-negative tumor variants.

**CONCLUDING REMARKS**

Although CAR T cell therapy has made great strides in the treatment of patients with advanced blood cancers; their success in solid tumors has been limited partly due to the cellular, molecular and physical barriers of the TME. Developing innovative approaches including arming CARTs with cytokine signaling modalities to overcome these barriers has important translational relevance. In this review, we outline several strategies to enhance the effectiveness of CAR T cells emphasizing roles for several cytokines, chemokines and their signaling pathways to overcome and/or prevent CAR T cell dysfunction or hyperactivation (Figure 2).

Genetically modifying cytokine/chemokine signaling pathways is an appealing approach to enhance the therapeutic properties of CAR T cell therapy for solid tumors. It is anticipated that new generations of cytokine/chemokine-gene-modified CAR T cells could effectively target/engage endogenous immune system to synergistically improve overall antitumor immunity and additionally prevent the appearance of antigen-negative tumor variants, and thereby, tumor relapse in the context of CAR T cell therapy. However, CRS and ICANS incidences remain main safety concerns as CRS and ICANS...
are potentially fatal adverse effect of CAR T cell therapy and genetic modifications of cytokines/chemokines that enhance CAR T cell function could exacerbate CRS and ICANS. To date, nearly all of studies have only investigated constitutive expression of single chemokine/cytokine. Thus, generation of CAR T cells engineered with an inducible chemokine/cytokine platform not only can increase efficacy but also guarantee safety of CAR T cell therapy.

Due to the fact that cytokine/chemokine gene expression profile can be various between different individuals or even at different stages of same tumor in an individual, hence; analysis of cytokine/chemokine gene expression signature in TME before CAR T cell therapy could aid scientists to individualize cytokine engineered-based CAR T cell therapy. Although genetic modification of cytokine signaling in CAR T cells have shown promising clinical results in both hematologic and non-hematologic cancers (Table 2), it seems combination of different genetic modification approaches could be beneficial as some of cytokines are immuno-inhibitory and others are immuno-stimulatory. Thus, modification of immunoinhibitory pathways using gene editing technologies (e.g. CRISPR/Cas9) or use of truncated cytokine receptors or cytokine traps alongside with overexpression of immuno-stimulatory cytokines may reprogram TME and significantly improve the efficacy of CAR T cell therapy.

Finally, it seems that a more comprehensive understanding of the relevant cellular and molecular adaptations to tumor cells and immunological processes in their surrounding microenvironment will help us develop new generations of cytokine/chemokine-gene-
### TABLE 2 | Selected clinical trials with cytokine/chemokine genetically-modified CAR T cells.

| Clinical trial ID | Status | Cytokine/Chemokine Genetic Modification | CAR | Condition or disease | Phase |
|-------------------|--------|----------------------------------------|-----|----------------------|-------|
| NCT04099799       | Recruiting | C7R¹ | GD2-CAR | High Grade Gioma/Diffuse Intrinsic Pontine Giroma/Medulloblastoma | Phase 1 |
| NCT03835832       | Recruiting | C7R | GD2-CAR | Relapsed/Refractory Neuroblastoma | Phase 1 |
| NCT03198646       | Recruiting | IL-7 and CCL19 | GPC3-CAR | Hepatocellular Carcinoma or Squamous Cell Lung Cancer | Phase 1 |
| NCT03929107       | Recruiting | IL-7 and CCL19 | CD19-CAR | Relapsed/Refractory B Cell Lymphoma | Phase 1 |
| NCT04377932       | Recruiting | IL-15 | GPC3-CAR | Relapsed/Refractory Diffuse Large B Cell Lymphoma | Phase 1 |
| NCT03932565       | Recruiting | IL-7 and CCL19 | CD19-CAR | Relapsed/Refractory Multiple Myeloma | Phase 1 |
| NCT03778346       | Recruiting | IL-7 and CCL19 | BCMA-CAR, CD138-CAR, CD38-CAR, Integrin β7-CAR, CS1-CAR | Solid Tumors | Phase 1 |
| NCT03932565       | Recruiting | IL-7 and CCL19, or IL-12 | Nectn4/FAP-CAR | Relapsed/Refractory Neuroblastoma | Phase 1 |
| NCT03721068       | Recruiting | IL-15 | GD2-CAR | Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma | Phase 1 |
| NCT04377902       | Recruiting | IL-15 | GPC3-CAR | Pediatric Solid Tumors | Phase 1 |
| NCT03579888       | Terminated | mIL-15-15² | CD19-CAR | B Cell Lymphoma and Leukemia | Phase 1 |
| NCT04715191       | Not yet recruiting | IL-15 and IL-21 | GPC3-CAR | Pediatric Solid Tumors | Phase 1 |
| NCT02498912       | Active, not recruiting | IL-12 | 4H11-CAR | Metastatic Colorectal Cancer | Phase 1 |
| NCT03542799       | Unknown | IL-12 | EGFR-CAR | Head and Neck Squamous Cell Carcinoma | Phase 1 |
| NCT01818323       | Recruiting | IL-4Ra and IL-2Rβ (4dβ) | T1E-CAR | Non-Small Cell Lung Cancer | Phase 1 |
| NCT04153799       | Recruiting | CXCR5 | EGFR-CAR | Refractory/Relapsed B Cell Lymphoma | Phase 1 |

modified CAR T cells that are more potent in overcoming the challenges of solid tumors.

### AUTHOR CONTRIBUTIONS

NG-S, SG, and HM conceived the idea of the manuscript. NG-S, BA, and TS performed the bibliographic research, wrote the original draft and drew the figures. HM, SG, and JH edited and critically revised the manuscript. All authors contributed to the article and approved the submitted version.

### REFERENCES

1. Miliotou AN, Papadopoulos LC. CAR T-Cell Therapy: A New Era in Cancer Immunotherapy. *Carr Pharm Biotechnol* (2018) 195:18. doi: 10.2174/138920101966180418095526
2. Ramalingam SS, Ovonikoko TK, Khuri FR. Lung Cancer: New Biological Challenges of solid tumors. *Frontiers Immunol* (2018) 9:1539. doi: 10.3389/fimmu.2018.00102
3. Cummins KD, Gill S. Anti-CD123 Chimeric Antigen Receptor T-Cells (CAR): An Evolving Treatment Strategy for Hematological Malignancies, and a Potential Ace-in-the-Hole Against Antigen-Negative Relapse. *Leuk Lymphoma* (2018) 59:1539-53. doi: 10.1080/10428194.2017.1375107
4. Brudno JN, Kochenderfer JN. Recent Advances in CAR T-Cell Toxicity: Mechanisms, Manifestations and Management. *Blood Rev* (2019) 34:45-55. doi: 10.1016/j.bjh.2018.11.002
5. Mirzaei HR, Rodriguez A, Shephard J, Brown CE, Badie B. Chimeric Antigen Receptors T Cell Therapy in Solid Tumor: Challenges and Clinical Applications. *Front Immunol* (2017) 8:1850. doi: 10.3389/fimmu.2017.01850
6. Rodriguez-Garcia A, Palazon A, Noguera-Ortega E, Powell DJJr., Guedian S. CAR-T Cells Hit the Tumor Microenvironment: Strategies to Overcome Tumor Escape. *Front Immunol* (2020) 11:109. doi: 10.3389/fimmu.2020.01109
7. Slaney CY, Kershaw MH, Darcy PK. Trafficking of T Cells Into Tumors. *Cancer Res* (2014) 74:7168-74. doi: 10.1158/0008-5472.CAN-14-2458
8. Jin J, Cheng J, Huang M, Luo H, Zhou J. Fueling Chimeric Antigen Receptor T Cells With Cytokines. *Am J Cancer Res* (2020) 10:6038-55.
9. Zhou J, Jin L, Wang F, Zhang Y, Liu B, Zhao T. Chimeric Antigen Receptor T (CAR-T) Cells Expanded With IL-7/IL-15 Mediate Superior Antitumor Effects. *Protein Cell* (2019) 10:764-9. doi: 10.1007/s13238-019-0674-γ
10. Borish LC, Steinke JW. 2. Cytokines and Chemokines. *J Allergy Clin Immunol* (2003) 111:S460–475. doi: 10.1067/caa.2003.108
11. Yeku OO, Purdon TJ, Koneru M, Spriggs D, Brentjens RJ. Armored CAR T Cells Enhance Antitumor Efficacy and Overcome the Tumor Microenvironment. *Sci Rep* (2017) 7:10541. doi: 10.1038/s41598-017-10940-8
12. Hawkins ER, D’Souza RR, Klamatsha A. Armored CAR T-Cells: The Next Chapter in T-Cell Cancer Immunotherapy. *Biol Targets Ther* (2021) 15:95-105. doi: 10.2147/BTT.S291768
13. Bak RO, Gomez-Ospina N, Porteus MH. Gene Editing on Center Stage. *Trends Genet* TIG (2018) 34:600-11. doi: 10.1016/j.tig.2018.05.004
14. Yi Y, Chai X, Zheng L, Zhang Y, Shen J, Hu B, et al. CRISPR-Edited CART With GM-CSF Knockout and Auto Secretion of IL6 and IL1 Blockers in Patients With Hematologic Malignancy. *Cell Discovery* (2021) 7:27. doi: 10.1038/s41421-021-00253-4
15. Kloss CC, Lee J, Zhang A, Chen F, Melenhorst JJ, Lacey SF, et al. Dominant-Negative TGF-β Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication. *Mol Ther* (2018) 26:1855-66. doi: 10.1038/s41397-018-00333-9

### FUNDING

This work was supported in part through funding provided by Tehran University of Medical Sciences (grants numbers 50756 and 50760, awarded to HM), St. Baldrick’s Foundation Scholar Award (SG), National Blood Foundation Scientific Research Grant Award (SG), as well as Office of the Assistant Secretary of Defense for Health Affairs through the Peer Reviewed Cancer Research Program under Award No. W81XWH-20-1-0417 (SG).
Frontiers in Immunology | www.frontiersin.org October 2021 | Volume 12 | Article 738456

Ghahri-Saremi et al. Genetic Modification of Cytokines in CART Cells

16. Wieser R, Attisano L, Wrana JL, Massaguet J. Signaling Activity of Transforming Growth Factor Beta Type II Receptors Lacking Specific Domains in the Cytoplasmic Region. Mol Cell Biol (1993) 13:7239–47. doi: 10.1128/MCB.13.12.7239

17. Liu Z, Chen O, Wall JR, Zheng M, Zhou Y, Wang L, et al. Systematic Comparison of 2A Peptides for Cloning Multi-Genes in a Polycistronic Vector. Sci Rep (2017) 7:2193. doi: 10.1038/s41598-017-02460-2

18. Moon EK, Carpenito C, Sun J, Wang LC, Kapoor V, Predina J, et al. Expression of a Functional CCR2 Receptor Enhances Tumor Localization and Tumor Eradication by Retargeted Human T Cells Expressing a Mesothelin-Specific Crigler Antibody Receptor. Clin Cancer Res (2011) 17:4719–30. doi: 10.1158/1078-0432.CCR-11-0351

19. Luo H, Wu X, Sun R, Su J, Wang Y, Dong P, et al. Target-Dependent Expression of IL12 by Synnych Sensor Receptor-Engineered NK92 Cells Increases the Antitumor Activities of CAR-T Cells. Front Oncol (2019) 9:1448. doi: 10.3389/fonc.2019.01448

20. Chmielewski M, Abken H. CAR T Cells Releasing IL-18 Convert to T-Reg (high) FoxO1(high) Effectors That Exhibit Augmented Activity Against Advanced Solid Tumors. Cell Rep (2017) 21:3205–19. doi: 10.1016/j.celrep.2017.11.063

21. Roybal KT, Williams JZ, Morsut L, Rupp LJ, Kolinko I, Choe JH, et al. Engineering T Cells With Customized Therapeutic Response Programs Using Synthetic Notch Receptors. Cell (2016) 167:419–32.e416. doi: 10.1016/j.cell.2016.12.011

22. Wang Y, Jiang H, Luo H, Sun Y, Shi B, Sun R, et al. An IL-4/21 Inverted Cytokine Receptor Improving CAR-T Cell Potency in Immunosuppressive Solid-Tumor Microenvironment. Front Immunol (2019) 10:1691. doi: 10.3389/fimmu.2019.01691

23. Batra SA, Rathi P, Guo L, Courtney AN, Fleurence J, Balzeau J, et al. Glypicanc-3-Specific CAR T Cells Coexpressing IL15 and IL21 Have Superior Expansion and Antitumor Activity Against Hepatocellular Carcinoma. Cancer Immunol Res (2020) 8:309–20. doi: 10.1158/2326-6066.CIR-19-0293

24. Adachi K, Kano Y, Nagai T, Okuyama N, Sakoda Y, Tamada K. IL-7 and CCL19 Expression in CAR-T Cells Improves Immune Cell Infiltration and CAR-T Cell Survival in the Tumor. Nat Biotechnol (2018) 36:346–51. doi: 10.1038/nbt.4086

25. Chen Y, Sun C, Landoni E, Predina J, Predina J, et al. Coexpression of IL7 and CCL21 Increases Efficacy of CAR-T Cells in Solid Tumors Without Requiring Preconditioned Lymphodepletion. Clin Cancer Res (2020) 26:5494–505. doi: 10.1158/1078-0432.CCR-20-0077

26. Hunter IV, Singh H, Najar AM, Switzer KC, MD, Matti S, et al. Tethered IL-15 Augments Antitumor Activity and Promotes a Stem-Cell Memory Subset in Tumor-Specific T Cells. Proc Natl Acad Sci (2016) 113:E7788–97. doi: 10.1073/pnas.1610544113

27. Jin L, Cao L, Zhu Y, Cao J, Li X, Zhou J, et al. Enhance Anti-Lung Tumor Efficacy of Chimeric Antigen Receptor-T Cells by Cytokie Expression of C-C Motif Chemokine Receptor 6. Sci Bull (2020) 8:803–12. doi: 10.1016/j.sciib.2020.12.027

28. Shum T, Omer B, Tashiro H, Kruse RL, Wagner DL, Parikh K, et al. Comparison of 2A Peptides for Cloning Multi-Genes in a Polycistronic Vector. Mol Ther Oncol (2017) 11:2915. doi: 10.1038/s41598-017-02462-2
Cell Lymphoma Treated by CD20-Directed Chimeric Antigen Receptor-Modified T Cells. *Clin Immunol (Orlando Fla.)* (2014) 155:160–70. doi: 10.1016/j.clim.2014.10.002

89. Fried S, Avigdor A, Bielerai B, Meir A, Besser MJ, Schachter J, et al. Early and Late Hematologic Toxicity Following CD19 CAR-T Cells. *Bone Marrow Transplant* (2019) 54:1643–50. doi: 10.1038/s41409-019-0487-3

90. Bonifant CL, Jackson HJ, Brentjens RJ, Curran KJ. Toxicity and Management in CAR T-Cell Therapy. *Mol Ther Oncol* (2016) 3:16011. doi: 10.1038/mto.2016.11

91. Kang L, Tang X, Zhang J, Li M, Xu N, Qi W, et al. Interleukin-6-Knockdown CAR-T Cells. *Recurrent Ovarian Cancer After Treatment With Mesothelin-Targeted Possible Compartmental Cytokine Release Syndrome in a Patient With Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. *N Engl J Med* (2017) 377:2531–44. doi: 10.1056/NEJMoa1707447

92. Tanyi JL, Stashwick C, Plesa G, Morgan MA, Porter D, Maus MV, et al. Possible Compartmental Cytokine Release Syndrome in a Patient With Recurrent Ovarian Cancer After Treatment With Mesothelin-Targeted CAR-T Cells. *J Immunother* (Hagerstown Md. 1997) (2017) 40:104–7. doi: 10.1097/CJI.0000000000000160